Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Polycystic Kidney, Autosomal Dominant | 107 | 2023 | 136 | 20.240 |
Why?
|
Hypertension | 74 | 2024 | 1139 | 6.630 |
Why?
|
Antihypertensive Agents | 53 | 2024 | 521 | 5.370 |
Why?
|
Blood Pressure | 59 | 2024 | 1143 | 4.650 |
Why?
|
Kidney | 53 | 2023 | 1240 | 4.430 |
Why?
|
Hydrochlorothiazide | 36 | 2024 | 76 | 4.010 |
Why?
|
Glomerular Filtration Rate | 46 | 2023 | 384 | 3.370 |
Why?
|
Atenolol | 24 | 2019 | 34 | 2.970 |
Why?
|
Antidiuretic Hormone Receptor Antagonists | 15 | 2020 | 29 | 2.350 |
Why?
|
Renal Insufficiency, Chronic | 15 | 2023 | 350 | 2.340 |
Why?
|
Kidney Failure, Chronic | 19 | 2022 | 509 | 2.240 |
Why?
|
Disease Progression | 54 | 2023 | 1531 | 2.200 |
Why?
|
Sodium Chloride Symporter Inhibitors | 14 | 2024 | 43 | 2.120 |
Why?
|
Polycystic Kidney Diseases | 5 | 2021 | 21 | 2.100 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 11 | 2019 | 90 | 2.010 |
Why?
|
Benzazepines | 13 | 2018 | 89 | 1.970 |
Why?
|
Pharmacogenomic Variants | 9 | 2019 | 41 | 1.780 |
Why?
|
Cysts | 10 | 2023 | 103 | 1.740 |
Why?
|
Adrenergic beta-Antagonists | 12 | 2019 | 152 | 1.730 |
Why?
|
Polymorphism, Single Nucleotide | 31 | 2020 | 2350 | 1.720 |
Why?
|
Pharmacogenetics | 22 | 2022 | 434 | 1.690 |
Why?
|
Benzimidazoles | 7 | 2019 | 140 | 1.330 |
Why?
|
Magnetic Resonance Imaging | 34 | 2023 | 3347 | 1.330 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 10 | 2018 | 231 | 1.290 |
Why?
|
Adult | 126 | 2024 | 25577 | 1.270 |
Why?
|
Humans | 195 | 2024 | 86281 | 1.270 |
Why?
|
Male | 147 | 2022 | 40860 | 1.210 |
Why?
|
Renin-Angiotensin System | 8 | 2018 | 133 | 1.210 |
Why?
|
Middle Aged | 124 | 2022 | 24957 | 1.210 |
Why?
|
Female | 146 | 2023 | 44405 | 1.190 |
Why?
|
Tetrazoles | 5 | 2019 | 50 | 1.180 |
Why?
|
Renin | 8 | 2020 | 78 | 1.090 |
Why?
|
Renal Insufficiency | 5 | 2022 | 114 | 0.990 |
Why?
|
Genome-Wide Association Study | 19 | 2019 | 1611 | 0.960 |
Why?
|
Adolescent | 56 | 2022 | 8968 | 0.920 |
Why?
|
Sodium | 4 | 2021 | 340 | 0.910 |
Why?
|
Chlorthalidone | 7 | 2021 | 25 | 0.910 |
Why?
|
Pain | 9 | 2021 | 389 | 0.870 |
Why?
|
Metoprolol | 7 | 2020 | 30 | 0.830 |
Why?
|
Organ Size | 22 | 2020 | 363 | 0.820 |
Why?
|
Young Adult | 49 | 2022 | 5961 | 0.810 |
Why?
|
Biomarkers | 17 | 2024 | 1709 | 0.800 |
Why?
|
Kidney Calculi | 2 | 2021 | 338 | 0.790 |
Why?
|
Diuretics | 11 | 2019 | 124 | 0.790 |
Why?
|
Treatment Outcome | 42 | 2021 | 7949 | 0.770 |
Why?
|
alpha-Glucosidases | 2 | 2017 | 7 | 0.770 |
Why?
|
TRPP Cation Channels | 10 | 2020 | 15 | 0.740 |
Why?
|
Nephrology | 4 | 2020 | 45 | 0.740 |
Why?
|
Mutation | 13 | 2020 | 3952 | 0.730 |
Why?
|
Apolipoprotein L1 | 1 | 2019 | 7 | 0.720 |
Why?
|
Drug Resistance | 2 | 2017 | 256 | 0.710 |
Why?
|
Prospective Studies | 29 | 2022 | 4194 | 0.690 |
Why?
|
Adrenergic beta-1 Receptor Antagonists | 4 | 2020 | 9 | 0.660 |
Why?
|
Retinal Dehydrogenase | 1 | 2017 | 6 | 0.640 |
Why?
|
Essential Hypertension | 7 | 2019 | 10 | 0.600 |
Why?
|
Hypertension, Renal | 2 | 2010 | 40 | 0.590 |
Why?
|
Genotype | 17 | 2020 | 1850 | 0.590 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2019 | 850 | 0.560 |
Why?
|
Severity of Illness Index | 13 | 2018 | 1796 | 0.550 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2016 | 79 | 0.550 |
Why?
|
Quality of Life | 7 | 2020 | 1575 | 0.550 |
Why?
|
Receptors, Adrenergic, beta | 1 | 2016 | 72 | 0.550 |
Why?
|
Angiotensin Receptor Antagonists | 3 | 2018 | 80 | 0.540 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 145 | 0.510 |
Why?
|
Kidney Diseases | 4 | 2016 | 418 | 0.500 |
Why?
|
Gastrointestinal Tract | 1 | 2016 | 191 | 0.490 |
Why?
|
Nephritis, Hereditary | 3 | 2022 | 5 | 0.490 |
Why?
|
Precision Medicine | 2 | 2019 | 394 | 0.490 |
Why?
|
Blood Glucose | 8 | 2018 | 873 | 0.460 |
Why?
|
Creatinine | 9 | 2022 | 337 | 0.450 |
Why?
|
Multivariate Analysis | 10 | 2021 | 997 | 0.450 |
Why?
|
Phenotype | 12 | 2020 | 2375 | 0.450 |
Why?
|
Double-Blind Method | 16 | 2022 | 1822 | 0.440 |
Why?
|
Oleanolic Acid | 2 | 2022 | 13 | 0.430 |
Why?
|
Infant, Low Birth Weight | 1 | 2012 | 58 | 0.430 |
Why?
|
Disease Management | 2 | 2014 | 327 | 0.430 |
Why?
|
Drug Therapy, Combination | 13 | 2014 | 893 | 0.430 |
Why?
|
Enalapril | 2 | 2009 | 18 | 0.410 |
Why?
|
Risk Factors | 19 | 2021 | 5397 | 0.400 |
Why?
|
Aged | 32 | 2022 | 18353 | 0.400 |
Why?
|
Risk Assessment | 12 | 2020 | 2253 | 0.400 |
Why?
|
Time Factors | 18 | 2020 | 5198 | 0.400 |
Why?
|
Cost of Illness | 3 | 2019 | 150 | 0.390 |
Why?
|
Hyperglycemia | 5 | 2018 | 176 | 0.390 |
Why?
|
Liver Diseases | 5 | 2022 | 238 | 0.380 |
Why?
|
Prognosis | 16 | 2023 | 3669 | 0.380 |
Why?
|
Predictive Value of Tests | 14 | 2020 | 1671 | 0.350 |
Why?
|
Sorting Nexins | 2 | 2020 | 4 | 0.350 |
Why?
|
Linear Models | 10 | 2017 | 419 | 0.350 |
Why?
|
Biphenyl Compounds | 5 | 2019 | 68 | 0.340 |
Why?
|
Logistic Models | 8 | 2017 | 1184 | 0.340 |
Why?
|
Staff Development | 1 | 2008 | 21 | 0.330 |
Why?
|
Longitudinal Studies | 11 | 2019 | 1015 | 0.330 |
Why?
|
Calcium Channel Blockers | 3 | 2019 | 203 | 0.330 |
Why?
|
Genetic Predisposition to Disease | 10 | 2017 | 2267 | 0.330 |
Why?
|
Faculty, Medical | 2 | 2020 | 178 | 0.330 |
Why?
|
Tumor Suppressor Proteins | 4 | 2016 | 279 | 0.330 |
Why?
|
United States | 17 | 2022 | 6637 | 0.320 |
Why?
|
Heart Rate | 3 | 2020 | 492 | 0.320 |
Why?
|
Patient Outcome Assessment | 2 | 2019 | 83 | 0.320 |
Why?
|
Analgesics | 1 | 2009 | 119 | 0.320 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2020 | 52 | 0.320 |
Why?
|
Image Processing, Computer-Assisted | 7 | 2020 | 1200 | 0.300 |
Why?
|
Patient Reported Outcome Measures | 4 | 2021 | 165 | 0.300 |
Why?
|
Caregivers | 4 | 2020 | 151 | 0.290 |
Why?
|
Albuminuria | 5 | 2016 | 153 | 0.290 |
Why?
|
Education, Medical | 2 | 2011 | 231 | 0.290 |
Why?
|
Odds Ratio | 4 | 2017 | 677 | 0.290 |
Why?
|
Ultrasonography | 6 | 2015 | 695 | 0.280 |
Why?
|
Blood Pressure Monitoring, Ambulatory | 8 | 2016 | 83 | 0.280 |
Why?
|
Polymorphism, Genetic | 7 | 2016 | 819 | 0.280 |
Why?
|
Academic Medical Centers | 1 | 2008 | 377 | 0.280 |
Why?
|
Kidney Function Tests | 6 | 2020 | 123 | 0.270 |
Why?
|
Lisinopril | 2 | 2014 | 14 | 0.260 |
Why?
|
Potassium | 4 | 2021 | 281 | 0.260 |
Why?
|
Age Factors | 9 | 2018 | 1842 | 0.260 |
Why?
|
Benzoates | 2 | 2014 | 44 | 0.260 |
Why?
|
Genetic Association Studies | 5 | 2018 | 294 | 0.250 |
Why?
|
Biomedical Research | 1 | 2008 | 375 | 0.250 |
Why?
|
Circulating MicroRNA | 1 | 2024 | 12 | 0.240 |
Why?
|
Nephrologists | 2 | 2020 | 9 | 0.240 |
Why?
|
Intracranial Aneurysm | 3 | 2020 | 158 | 0.240 |
Why?
|
Uric Acid | 5 | 2019 | 139 | 0.230 |
Why?
|
Research Design | 5 | 2021 | 594 | 0.230 |
Why?
|
Alanine Transaminase | 2 | 2020 | 73 | 0.230 |
Why?
|
Chi-Square Distribution | 4 | 2017 | 362 | 0.230 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 1168 | 0.230 |
Why?
|
Gene Expression Profiling | 3 | 2018 | 1381 | 0.230 |
Why?
|
Consensus | 4 | 2020 | 333 | 0.220 |
Why?
|
Cystatin C | 1 | 2022 | 31 | 0.220 |
Why?
|
Medical History Taking | 2 | 2017 | 80 | 0.210 |
Why?
|
Metabolic Syndrome | 2 | 2015 | 141 | 0.210 |
Why?
|
Image Interpretation, Computer-Assisted | 3 | 2017 | 663 | 0.210 |
Why?
|
Metabolic Diseases | 2 | 2021 | 48 | 0.210 |
Why?
|
Pregnancy Outcome | 1 | 2023 | 247 | 0.210 |
Why?
|
Aldosterone | 4 | 2015 | 65 | 0.200 |
Why?
|
Calcium, Dietary | 1 | 2021 | 63 | 0.200 |
Why?
|
Fasting | 4 | 2015 | 161 | 0.200 |
Why?
|
Cohort Studies | 9 | 2020 | 2759 | 0.200 |
Why?
|
Pharmacogenomic Testing | 2 | 2019 | 97 | 0.200 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 73 | 0.200 |
Why?
|
Receptors, Adrenergic, beta-2 | 2 | 2019 | 36 | 0.190 |
Why?
|
Calcium Phosphates | 1 | 2021 | 77 | 0.190 |
Why?
|
Bone Diseases | 1 | 2020 | 54 | 0.190 |
Why?
|
Child | 6 | 2022 | 6913 | 0.190 |
Why?
|
Liver | 4 | 2022 | 1229 | 0.190 |
Why?
|
Verapamil | 2 | 2017 | 48 | 0.180 |
Why?
|
Metabolomics | 3 | 2017 | 67 | 0.180 |
Why?
|
Advisory Committees | 1 | 2020 | 90 | 0.180 |
Why?
|
Georgia | 2 | 2017 | 34 | 0.180 |
Why?
|
ADP-ribosyl Cyclase | 1 | 2019 | 6 | 0.180 |
Why?
|
Membrane Proteins | 3 | 2015 | 1194 | 0.180 |
Why?
|
Calcium Oxalate | 1 | 2021 | 185 | 0.180 |
Why?
|
Chromosomes, Human, Pair 2 | 1 | 2019 | 85 | 0.180 |
Why?
|
Gastric Bypass | 1 | 2021 | 110 | 0.180 |
Why?
|
Models, Biological | 2 | 2019 | 1748 | 0.180 |
Why?
|
Sequence Analysis, DNA | 3 | 2019 | 853 | 0.180 |
Why?
|
Reproducibility of Results | 11 | 2019 | 2699 | 0.180 |
Why?
|
Pregnancy | 2 | 2023 | 2885 | 0.180 |
Why?
|
Glycopeptides | 1 | 2019 | 16 | 0.180 |
Why?
|
Genetic Testing | 2 | 2017 | 535 | 0.170 |
Why?
|
Mortality | 1 | 2020 | 148 | 0.170 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 107 | 0.170 |
Why?
|
Indoles | 2 | 2019 | 318 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2022 | 1372 | 0.170 |
Why?
|
Genetic Markers | 2 | 2017 | 476 | 0.170 |
Why?
|
Gadolinium | 2 | 2010 | 103 | 0.170 |
Why?
|
Bestrophins | 1 | 2018 | 1 | 0.170 |
Why?
|
Genotyping Techniques | 2 | 2019 | 68 | 0.170 |
Why?
|
Iothalamic Acid | 3 | 2015 | 11 | 0.170 |
Why?
|
Hydroxymethylglutaryl-CoA Synthase | 1 | 2018 | 3 | 0.160 |
Why?
|
Obesity | 2 | 2017 | 962 | 0.160 |
Why?
|
Angiopoietin-2 | 1 | 2018 | 15 | 0.160 |
Why?
|
Sex Factors | 5 | 2021 | 1053 | 0.160 |
Why?
|
Life Style | 1 | 2019 | 188 | 0.160 |
Why?
|
Emotional Adjustment | 1 | 2017 | 2 | 0.160 |
Why?
|
Sphingolipids | 1 | 2017 | 20 | 0.160 |
Why?
|
Caffeine | 1 | 2018 | 81 | 0.160 |
Why?
|
Muscle Proteins | 1 | 2018 | 132 | 0.160 |
Why?
|
Florida | 1 | 2017 | 54 | 0.160 |
Why?
|
Endpoint Determination | 1 | 2017 | 60 | 0.160 |
Why?
|
Age of Onset | 2 | 2012 | 306 | 0.160 |
Why?
|
Blood Pressure Determination | 3 | 2016 | 90 | 0.160 |
Why?
|
Cardiovascular Diseases | 3 | 2020 | 826 | 0.160 |
Why?
|
Receptors, Odorant | 1 | 2018 | 37 | 0.150 |
Why?
|
DNA Mutational Analysis | 2 | 2017 | 526 | 0.150 |
Why?
|
Antigens, CD | 1 | 2019 | 457 | 0.150 |
Why?
|
Follow-Up Studies | 9 | 2017 | 3616 | 0.150 |
Why?
|
Regression Analysis | 6 | 2013 | 595 | 0.150 |
Why?
|
Chemokine CCL2 | 1 | 2017 | 47 | 0.150 |
Why?
|
Drug Combinations | 1 | 2017 | 222 | 0.150 |
Why?
|
Diet, Sodium-Restricted | 1 | 2016 | 14 | 0.150 |
Why?
|
Sodium Chloride, Dietary | 1 | 2016 | 11 | 0.150 |
Why?
|
Oxidative Stress | 1 | 2020 | 446 | 0.150 |
Why?
|
Early Diagnosis | 2 | 2008 | 131 | 0.150 |
Why?
|
Vasodilator Agents | 1 | 2017 | 152 | 0.150 |
Why?
|
Time-to-Treatment | 1 | 2018 | 97 | 0.150 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 151 | 0.150 |
Why?
|
Patient Selection | 4 | 2019 | 685 | 0.150 |
Why?
|
Fibroblast Growth Factors | 1 | 2017 | 80 | 0.150 |
Why?
|
Fatigue | 1 | 2017 | 174 | 0.150 |
Why?
|
Epoxide Hydrolases | 1 | 2016 | 7 | 0.150 |
Why?
|
Societies, Medical | 1 | 2020 | 572 | 0.140 |
Why?
|
Pain Management | 1 | 2017 | 126 | 0.140 |
Why?
|
Databases, Factual | 2 | 2021 | 808 | 0.140 |
Why?
|
Genetic Loci | 2 | 2019 | 250 | 0.140 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 2 | 1 | 2015 | 2 | 0.140 |
Why?
|
Abdomen | 1 | 2016 | 121 | 0.140 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2016 | 64 | 0.140 |
Why?
|
Cholesterol, HDL | 2 | 2013 | 165 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 5 | 2017 | 1958 | 0.130 |
Why?
|
Kidney Transplantation | 1 | 2022 | 846 | 0.130 |
Why?
|
Amino Acids, Aromatic | 1 | 2015 | 3 | 0.130 |
Why?
|
Delphi Technique | 3 | 2020 | 79 | 0.130 |
Why?
|
Amino Acids, Branched-Chain | 1 | 2015 | 7 | 0.130 |
Why?
|
Renal Circulation | 2 | 2006 | 61 | 0.130 |
Why?
|
Plasma Membrane Calcium-Transporting ATPases | 1 | 2014 | 5 | 0.130 |
Why?
|
Heart Ventricles | 2 | 2011 | 760 | 0.130 |
Why?
|
Receptors, Cell Surface | 1 | 2016 | 286 | 0.130 |
Why?
|
Hepatomegaly | 1 | 2014 | 15 | 0.130 |
Why?
|
ROC Curve | 4 | 2020 | 752 | 0.130 |
Why?
|
Personnel Selection | 2 | 2020 | 59 | 0.130 |
Why?
|
Multicenter Studies as Topic | 2 | 2017 | 156 | 0.120 |
Why?
|
Body Height | 3 | 2020 | 99 | 0.120 |
Why?
|
Patient Safety | 1 | 2017 | 212 | 0.120 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 645 | 0.120 |
Why?
|
MicroRNAs | 1 | 2019 | 534 | 0.120 |
Why?
|
Vascular Stiffness | 1 | 2014 | 26 | 0.120 |
Why?
|
Arterial Pressure | 1 | 2014 | 38 | 0.120 |
Why?
|
Combined Modality Therapy | 1 | 2017 | 1680 | 0.120 |
Why?
|
Gene Rearrangement | 2 | 2018 | 170 | 0.120 |
Why?
|
Peptides | 1 | 2017 | 639 | 0.120 |
Why?
|
Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 15 | 0.120 |
Why?
|
Fructokinases | 1 | 2013 | 1 | 0.110 |
Why?
|
Glucose Transporter Type 5 | 1 | 2013 | 6 | 0.110 |
Why?
|
Body Mass Index | 3 | 2017 | 770 | 0.110 |
Why?
|
Glucose Transporter Type 2 | 1 | 2013 | 10 | 0.110 |
Why?
|
Contrast Media | 4 | 2015 | 1076 | 0.110 |
Why?
|
Amino Acids | 1 | 2014 | 252 | 0.110 |
Why?
|
Linkage Disequilibrium | 4 | 2019 | 473 | 0.110 |
Why?
|
Administration, Oral | 2 | 2020 | 683 | 0.110 |
Why?
|
Hypertrophy, Left Ventricular | 2 | 2011 | 73 | 0.110 |
Why?
|
G-Protein-Coupled Receptor Kinase 4 | 1 | 2012 | 2 | 0.110 |
Why?
|
Hypoxia | 1 | 2018 | 638 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2017 | 378 | 0.110 |
Why?
|
Metabolome | 1 | 2013 | 47 | 0.110 |
Why?
|
Organic Cation Transport Proteins | 1 | 2012 | 13 | 0.110 |
Why?
|
Organic Anion Transporters | 1 | 2012 | 27 | 0.110 |
Why?
|
Transcriptome | 1 | 2017 | 574 | 0.110 |
Why?
|
Aorta | 1 | 2014 | 280 | 0.110 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2013 | 165 | 0.100 |
Why?
|
Algorithms | 2 | 2018 | 1828 | 0.100 |
Why?
|
Urinalysis | 3 | 2021 | 33 | 0.100 |
Why?
|
Hormone Antagonists | 1 | 2011 | 20 | 0.100 |
Why?
|
Proteome | 1 | 2013 | 124 | 0.100 |
Why?
|
Pain Measurement | 2 | 2013 | 321 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 4 | 2020 | 2594 | 0.100 |
Why?
|
Lysine | 1 | 2012 | 147 | 0.100 |
Why?
|
Health Status | 1 | 2013 | 360 | 0.100 |
Why?
|
G-Protein-Coupled Receptor Kinase 5 | 1 | 2011 | 4 | 0.100 |
Why?
|
Proteomics | 1 | 2013 | 211 | 0.100 |
Why?
|
G-Protein-Coupled Receptor Kinase 2 | 1 | 2011 | 22 | 0.100 |
Why?
|
Specialization | 1 | 2011 | 65 | 0.100 |
Why?
|
Circadian Rhythm | 1 | 2013 | 303 | 0.100 |
Why?
|
Kidney Diseases, Cystic | 1 | 2010 | 23 | 0.100 |
Why?
|
Lipopolysaccharide Receptors | 1 | 2010 | 23 | 0.100 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2010 | 378 | 0.090 |
Why?
|
Signal Transduction | 3 | 2016 | 3233 | 0.090 |
Why?
|
Dialysis | 1 | 2010 | 24 | 0.090 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2010 | 9 | 0.090 |
Why?
|
Hamartoma | 1 | 2010 | 31 | 0.090 |
Why?
|
Mass Spectrometry | 3 | 2017 | 188 | 0.090 |
Why?
|
Republic of Korea | 2 | 2020 | 31 | 0.090 |
Why?
|
France | 2 | 2020 | 47 | 0.090 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2007 | 69 | 0.090 |
Why?
|
Obesity, Abdominal | 1 | 2009 | 8 | 0.090 |
Why?
|
Histones | 1 | 2012 | 309 | 0.090 |
Why?
|
Australia | 2 | 2020 | 99 | 0.090 |
Why?
|
Teaching | 1 | 2011 | 147 | 0.090 |
Why?
|
Kininogens | 1 | 2009 | 6 | 0.090 |
Why?
|
Hypokalemia | 1 | 2009 | 29 | 0.090 |
Why?
|
Homeodomain Proteins | 1 | 2013 | 535 | 0.090 |
Why?
|
Alleles | 3 | 2019 | 1127 | 0.090 |
Why?
|
Renal Artery | 1 | 2010 | 64 | 0.090 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 468 | 0.090 |
Why?
|
Surveys and Questionnaires | 3 | 2017 | 2495 | 0.090 |
Why?
|
Stakeholder Participation | 2 | 2020 | 19 | 0.090 |
Why?
|
Amlodipine | 2 | 2015 | 37 | 0.090 |
Why?
|
Body Weight | 2 | 2008 | 459 | 0.090 |
Why?
|
DNA-Binding Proteins | 1 | 2015 | 1208 | 0.090 |
Why?
|
Retrospective Studies | 6 | 2022 | 8431 | 0.090 |
Why?
|
Focus Groups | 2 | 2020 | 153 | 0.080 |
Why?
|
Internet | 1 | 2011 | 309 | 0.080 |
Why?
|
Family Relations | 1 | 2008 | 35 | 0.080 |
Why?
|
Career Mobility | 1 | 2008 | 31 | 0.080 |
Why?
|
Chromosomes, Human, Pair 12 | 1 | 2008 | 65 | 0.080 |
Why?
|
Phantoms, Imaging | 3 | 2010 | 426 | 0.080 |
Why?
|
Educational Status | 1 | 2009 | 187 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2008 | 80 | 0.080 |
Why?
|
Job Satisfaction | 1 | 2008 | 73 | 0.080 |
Why?
|
Program Development | 1 | 2008 | 124 | 0.080 |
Why?
|
Forecasting | 2 | 2016 | 303 | 0.080 |
Why?
|
Practice Guidelines as Topic | 1 | 2015 | 1030 | 0.080 |
Why?
|
Mentors | 1 | 2008 | 76 | 0.080 |
Why?
|
Bisoprolol | 2 | 2019 | 3 | 0.080 |
Why?
|
Cross-Sectional Studies | 3 | 2022 | 1610 | 0.080 |
Why?
|
Workload | 1 | 2008 | 128 | 0.080 |
Why?
|
Cooperative Behavior | 1 | 2008 | 174 | 0.080 |
Why?
|
Meta-Analysis as Topic | 2 | 2019 | 87 | 0.080 |
Why?
|
Case-Control Studies | 4 | 2015 | 1801 | 0.080 |
Why?
|
Career Choice | 1 | 2008 | 139 | 0.070 |
Why?
|
Renal Artery Obstruction | 1 | 2007 | 39 | 0.070 |
Why?
|
Nitric Oxide Synthase | 2 | 2005 | 125 | 0.070 |
Why?
|
Incidence | 3 | 2018 | 1568 | 0.070 |
Why?
|
Clinical Decision-Making | 2 | 2019 | 255 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 1 | 2010 | 589 | 0.070 |
Why?
|
Mutation, Missense | 2 | 2019 | 276 | 0.070 |
Why?
|
Proportional Hazards Models | 2 | 2018 | 857 | 0.070 |
Why?
|
Gene Frequency | 4 | 2015 | 676 | 0.070 |
Why?
|
Electrophoresis, Capillary | 2 | 2017 | 12 | 0.070 |
Why?
|
Area Under Curve | 2 | 2017 | 334 | 0.070 |
Why?
|
Automation, Laboratory | 2 | 2016 | 10 | 0.070 |
Why?
|
Metabolic Networks and Pathways | 2 | 2017 | 78 | 0.070 |
Why?
|
Registries | 1 | 2009 | 702 | 0.070 |
Why?
|
Losartan | 2 | 2015 | 42 | 0.070 |
Why?
|
Lipid Metabolism | 2 | 2017 | 196 | 0.060 |
Why?
|
Natriuresis | 2 | 2016 | 30 | 0.060 |
Why?
|
Microfilament Proteins | 2 | 2017 | 206 | 0.060 |
Why?
|
Up-Regulation | 2 | 2017 | 710 | 0.060 |
Why?
|
Polycystic Kidney, Autosomal Recessive | 1 | 2003 | 2 | 0.060 |
Why?
|
Thiazides | 1 | 2024 | 19 | 0.060 |
Why?
|
Fabry Disease | 1 | 2003 | 6 | 0.060 |
Why?
|
Osmolar Concentration | 2 | 2016 | 181 | 0.060 |
Why?
|
Risk | 2 | 2017 | 673 | 0.060 |
Why?
|
Tuberous Sclerosis | 1 | 2003 | 28 | 0.060 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2003 | 20 | 0.060 |
Why?
|
Genetic Heterogeneity | 1 | 2003 | 62 | 0.060 |
Why?
|
Diastole | 2 | 2019 | 143 | 0.060 |
Why?
|
Basement Membrane | 1 | 2003 | 54 | 0.060 |
Why?
|
Kidney Glomerulus | 1 | 2003 | 123 | 0.060 |
Why?
|
Hyperaldosteronism | 1 | 2002 | 13 | 0.060 |
Why?
|
Peptidyl-Dipeptidase A | 1 | 2002 | 32 | 0.060 |
Why?
|
Syndrome | 1 | 2003 | 446 | 0.060 |
Why?
|
Mice | 4 | 2020 | 11313 | 0.050 |
Why?
|
Genetic Variation | 1 | 2009 | 1349 | 0.050 |
Why?
|
Demography | 2 | 2013 | 177 | 0.050 |
Why?
|
Outpatients | 1 | 2022 | 94 | 0.050 |
Why?
|
Drug Administration Schedule | 2 | 2015 | 916 | 0.050 |
Why?
|
RNA, Messenger | 2 | 2017 | 1975 | 0.050 |
Why?
|
Bicarbonates | 1 | 2021 | 60 | 0.050 |
Why?
|
Systole | 2 | 2015 | 129 | 0.050 |
Why?
|
Preoperative Period | 1 | 2021 | 91 | 0.050 |
Why?
|
Parents | 1 | 2003 | 269 | 0.050 |
Why?
|
Pedigree | 2 | 2016 | 966 | 0.050 |
Why?
|
Urine | 1 | 2021 | 90 | 0.050 |
Why?
|
Administrative Personnel | 1 | 2020 | 8 | 0.050 |
Why?
|
Minerals | 1 | 2020 | 22 | 0.050 |
Why?
|
Salaries and Fringe Benefits | 1 | 2020 | 23 | 0.050 |
Why?
|
Pregnancy Complications | 1 | 2003 | 336 | 0.050 |
Why?
|
Sulfonamides | 1 | 2002 | 299 | 0.050 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2020 | 21 | 0.050 |
Why?
|
Lipoproteins, HDL | 2 | 2011 | 96 | 0.050 |
Why?
|
Chemical and Drug Induced Liver Injury | 1 | 2020 | 68 | 0.050 |
Why?
|
Efficiency | 1 | 2020 | 40 | 0.050 |
Why?
|
Asia | 1 | 2020 | 94 | 0.050 |
Why?
|
Africa | 1 | 2020 | 98 | 0.050 |
Why?
|
Postoperative Period | 1 | 2021 | 303 | 0.050 |
Why?
|
Genomics | 2 | 2017 | 710 | 0.050 |
Why?
|
Kidney Tubules, Proximal | 1 | 2020 | 61 | 0.050 |
Why?
|
Survival Analysis | 1 | 2003 | 1536 | 0.050 |
Why?
|
Attitude | 1 | 2020 | 126 | 0.050 |
Why?
|
GPI-Linked Proteins | 1 | 2019 | 50 | 0.040 |
Why?
|
NADPH Oxidases | 1 | 2020 | 81 | 0.040 |
Why?
|
Epithelial Sodium Channels | 2 | 2012 | 7 | 0.040 |
Why?
|
Self Concept | 1 | 2020 | 133 | 0.040 |
Why?
|
Psychometrics | 1 | 2021 | 327 | 0.040 |
Why?
|
Heterotrimeric GTP-Binding Proteins | 1 | 2019 | 11 | 0.040 |
Why?
|
Receptors, Adrenergic, beta-1 | 1 | 2019 | 8 | 0.040 |
Why?
|
Mosaicism | 1 | 2019 | 67 | 0.040 |
Why?
|
Observer Variation | 2 | 2013 | 601 | 0.040 |
Why?
|
Heart | 1 | 2002 | 538 | 0.040 |
Why?
|
Patients | 1 | 2020 | 100 | 0.040 |
Why?
|
Activities of Daily Living | 1 | 2020 | 202 | 0.040 |
Why?
|
Oxidation-Reduction | 1 | 2020 | 373 | 0.040 |
Why?
|
Patient Acuity | 1 | 2019 | 32 | 0.040 |
Why?
|
Image Enhancement | 2 | 2016 | 563 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 274 | 0.040 |
Why?
|
Renal Dialysis | 1 | 2022 | 354 | 0.040 |
Why?
|
Animals | 5 | 2020 | 26518 | 0.040 |
Why?
|
Qualitative Research | 1 | 2020 | 256 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2013 | 1987 | 0.040 |
Why?
|
Dehydration | 1 | 2018 | 18 | 0.040 |
Why?
|
Diuresis | 1 | 2018 | 29 | 0.040 |
Why?
|
Pseudouridine | 1 | 2019 | 19 | 0.040 |
Why?
|
Observational Studies as Topic | 1 | 2018 | 48 | 0.040 |
Why?
|
Protein Transport | 1 | 2020 | 410 | 0.040 |
Why?
|
Angiotensin II | 1 | 2018 | 94 | 0.040 |
Why?
|
Triglycerides | 2 | 2011 | 232 | 0.040 |
Why?
|
Serine C-Palmitoyltransferase | 1 | 2017 | 4 | 0.040 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 547 | 0.040 |
Why?
|
Siloxanes | 1 | 2017 | 5 | 0.040 |
Why?
|
CCAAT-Enhancer-Binding Protein-delta | 1 | 2017 | 4 | 0.040 |
Why?
|
Clinical Protocols | 1 | 2018 | 155 | 0.040 |
Why?
|
Ethnopharmacology | 1 | 2017 | 2 | 0.040 |
Why?
|
Health Personnel | 1 | 2020 | 202 | 0.040 |
Why?
|
Transcription Factors | 2 | 2017 | 1555 | 0.040 |
Why?
|
Infant, Newborn | 1 | 2003 | 2369 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2017 | 16 | 0.040 |
Why?
|
Healthcare Disparities | 1 | 2022 | 369 | 0.040 |
Why?
|
Attitude to Health | 1 | 2019 | 220 | 0.040 |
Why?
|
Bilirubin | 1 | 2017 | 124 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 567 | 0.040 |
Why?
|
Nitriles | 1 | 2017 | 145 | 0.040 |
Why?
|
Reference Values | 2 | 2013 | 673 | 0.040 |
Why?
|
Reactive Oxygen Species | 1 | 2020 | 480 | 0.040 |
Why?
|
Half-Life | 1 | 2017 | 96 | 0.040 |
Why?
|
Renal Elimination | 1 | 2016 | 8 | 0.040 |
Why?
|
Stress, Psychological | 1 | 2020 | 313 | 0.040 |
Why?
|
DCC Receptor | 1 | 2016 | 4 | 0.040 |
Why?
|
Overweight | 1 | 2017 | 118 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2019 | 202 | 0.040 |
Why?
|
Single-Blind Method | 1 | 2016 | 151 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 859 | 0.040 |
Why?
|
Hypernatremia | 1 | 2016 | 9 | 0.040 |
Why?
|
Immunoprecipitation | 1 | 2016 | 134 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2018 | 360 | 0.030 |
Why?
|
Cell Adhesion Molecules | 1 | 2017 | 163 | 0.030 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2019 | 455 | 0.030 |
Why?
|
CRISPR-Cas Systems | 1 | 2016 | 70 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2016 | 314 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2017 | 253 | 0.030 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2016 | 416 | 0.030 |
Why?
|
Morbidity | 1 | 2016 | 146 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2016 | 268 | 0.030 |
Why?
|
Cell Line | 1 | 2020 | 2466 | 0.030 |
Why?
|
Aldehyde Oxidoreductases | 1 | 2015 | 4 | 0.030 |
Why?
|
Finland | 1 | 2015 | 29 | 0.030 |
Why?
|
Italy | 1 | 2015 | 106 | 0.030 |
Why?
|
Dioxygenases | 1 | 2015 | 74 | 0.030 |
Why?
|
Puerto Rico | 1 | 2014 | 31 | 0.030 |
Why?
|
Chloride Channels | 1 | 2015 | 42 | 0.030 |
Why?
|
Prevalence | 2 | 2011 | 1239 | 0.030 |
Why?
|
Survival Rate | 1 | 2018 | 1856 | 0.030 |
Why?
|
Sodium Channels | 2 | 2005 | 129 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 104 | 0.030 |
Why?
|
Liver Function Tests | 1 | 2014 | 93 | 0.030 |
Why?
|
Gene Dosage | 1 | 2015 | 207 | 0.030 |
Why?
|
Gene Duplication | 1 | 2015 | 125 | 0.030 |
Why?
|
Low Density Lipoprotein Receptor-Related Protein-5 | 1 | 2013 | 4 | 0.030 |
Why?
|
Glucose Intolerance | 1 | 2014 | 96 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2015 | 399 | 0.030 |
Why?
|
Lipase | 1 | 2013 | 22 | 0.030 |
Why?
|
N-Acetylgalactosaminyltransferases | 1 | 2013 | 12 | 0.030 |
Why?
|
DNA Copy Number Variations | 1 | 2015 | 171 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2013 | 48 | 0.030 |
Why?
|
Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2013 | 41 | 0.030 |
Why?
|
Protein Kinase C-alpha | 1 | 2013 | 27 | 0.030 |
Why?
|
Nedd4 Ubiquitin Protein Ligases | 1 | 2013 | 14 | 0.030 |
Why?
|
Radioimmunoassay | 1 | 2013 | 155 | 0.030 |
Why?
|
Chromosomes, Human, Pair 17 | 1 | 2013 | 110 | 0.030 |
Why?
|
Polymerase Chain Reaction | 1 | 2015 | 927 | 0.030 |
Why?
|
Pattern Recognition, Automated | 1 | 2014 | 217 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 144 | 0.030 |
Why?
|
Receptors, Interleukin-18 | 1 | 2012 | 2 | 0.030 |
Why?
|
Chromosomes, Human, Pair 16 | 1 | 2012 | 79 | 0.030 |
Why?
|
Amino Acid Sequence | 1 | 2016 | 2062 | 0.030 |
Why?
|
Rats, Mutant Strains | 1 | 2012 | 23 | 0.030 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2012 | 106 | 0.030 |
Why?
|
Lipocalin-2 | 1 | 2012 | 38 | 0.030 |
Why?
|
Interleukin-18 | 1 | 2012 | 26 | 0.030 |
Why?
|
Lipocalins | 1 | 2012 | 35 | 0.030 |
Why?
|
Cluster Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
Acute-Phase Proteins | 1 | 2012 | 37 | 0.030 |
Why?
|
Signal-To-Noise Ratio | 1 | 2012 | 94 | 0.030 |
Why?
|
Oncogene Proteins | 1 | 2012 | 59 | 0.030 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 329 | 0.030 |
Why?
|
Lipoproteins, LDL | 1 | 2011 | 83 | 0.030 |
Why?
|
Sample Size | 1 | 2012 | 130 | 0.030 |
Why?
|
Aged, 80 and over | 2 | 2014 | 6481 | 0.030 |
Why?
|
Receptors, Vasopressin | 1 | 2011 | 7 | 0.030 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2012 | 114 | 0.020 |
Why?
|
North America | 1 | 2011 | 179 | 0.020 |
Why?
|
Methylation | 1 | 2012 | 251 | 0.020 |
Why?
|
Japan | 1 | 2011 | 307 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2016 | 2810 | 0.020 |
Why?
|
Pulsatile Flow | 1 | 2010 | 49 | 0.020 |
Why?
|
Cardiac-Gated Imaging Techniques | 1 | 2010 | 19 | 0.020 |
Why?
|
Haplotypes | 1 | 2012 | 642 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2010 | 290 | 0.020 |
Why?
|
Hyperuricemia | 1 | 2009 | 27 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2010 | 197 | 0.020 |
Why?
|
Hypertriglyceridemia | 1 | 2009 | 67 | 0.020 |
Why?
|
Databases as Topic | 1 | 2009 | 92 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2017 | 1917 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2012 | 1214 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2010 | 182 | 0.020 |
Why?
|
Animals, Newborn | 1 | 2010 | 509 | 0.020 |
Why?
|
Gadolinium DTPA | 1 | 2010 | 261 | 0.020 |
Why?
|
Family Health | 1 | 2008 | 162 | 0.020 |
Why?
|
Proteins | 1 | 2013 | 777 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2012 | 1537 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 347 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2010 | 264 | 0.020 |
Why?
|
Probability | 1 | 2008 | 355 | 0.020 |
Why?
|
Hypertension, Renovascular | 1 | 2007 | 14 | 0.020 |
Why?
|
Gene Deletion | 1 | 2008 | 328 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2012 | 1918 | 0.020 |
Why?
|
Software | 1 | 2011 | 650 | 0.020 |
Why?
|
Curriculum | 1 | 2011 | 537 | 0.020 |
Why?
|
Incidental Findings | 1 | 2007 | 95 | 0.020 |
Why?
|
WNK Lysine-Deficient Protein Kinase 1 | 1 | 2005 | 1 | 0.020 |
Why?
|
Minor Histocompatibility Antigens | 1 | 2005 | 39 | 0.020 |
Why?
|
Anthropometry | 1 | 2005 | 74 | 0.020 |
Why?
|
Cytochrome P-450 CYP11B2 | 1 | 2005 | 3 | 0.020 |
Why?
|
Physicians' Offices | 1 | 2005 | 2 | 0.020 |
Why?
|
Rats | 1 | 2012 | 3984 | 0.020 |
Why?
|
Genome | 1 | 2008 | 371 | 0.020 |
Why?
|
Imaging, Three-Dimensional | 1 | 2009 | 579 | 0.020 |
Why?
|
Biological Transport | 1 | 2005 | 396 | 0.020 |
Why?
|
Insulin | 1 | 2009 | 1159 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2006 | 912 | 0.020 |
Why?
|
Atherosclerosis | 1 | 2007 | 243 | 0.020 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2003 | 88 | 0.010 |
Why?
|
Cholesterol | 1 | 2005 | 356 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2010 | 2227 | 0.010 |
Why?
|
African Americans | 1 | 2002 | 10 | 0.010 |
Why?
|
Cerebral Angiography | 1 | 2003 | 196 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2002 | 307 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 801 | 0.010 |
Why?
|
Hemodynamics | 1 | 2003 | 710 | 0.010 |
Why?
|
Recurrence | 1 | 2003 | 1137 | 0.010 |
Why?
|
Echocardiography | 1 | 2002 | 911 | 0.010 |
Why?
|